Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

PURPOSE: Buparlisib, an oral reversible inhibitor of all class I phosphoinositide-3-kinases, has shown antitumoral activity against estrogen receptor (ER)-positive breast cancer cell lines and xenografts, alone and with endocrine therapy. This phase Ib study evaluated buparlisib plus letrozole'...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Mayer, Ingrid A., Abramson, Vandana G., Isakoff, Steven J., Forero, Andres, Balko, Justin M., Kuba, María Gabriela, Sanders, Melinda E., Yap, Jeffrey T., Van den Abbeele, Annick D., Li, Yisheng, Cantley, Lewis C., Winer, Eric, Arteaga, Carlos L.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2014
Teme:
ORIGINAL REPORTS
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3986383/
https://ncbi.nlm.nih.gov/pubmed/24663045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.54.0518
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items